A Phase 2, Proof-of-Concept Study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the Treatment for Alcohol Use Disorder (AUD)
Latest Information Update: 10 Aug 2020
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Alcoholism
- Focus Proof of concept; Therapeutic Use
- Sponsors Tonix Pharmaceuticals Holding Corp
Most Recent Events
- 06 Aug 2020 According to a Tonix Pharmaceuticals Holding Corp media release, U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 proof-of-concept study using TNX-102 SL for treatment of alcohol use disorder (AUD)
- 27 Nov 2019 New trial record